The Evaluation of Tenofovir Alafenamide Containing Regimens vs. Tenofovir Disoproxil Fumarate Containing Regimens on Renal Outcomes for Prevention, and Treatment of HIV and/or HBV Treatment: a Systematic Literature Review and Meta-analysis

Study type

• Study type:
  Non-interventional study

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  TENOFOVIR ALAFENAMIDE

  TENOFOVIR DISOPROXIL FUMARATE
• Anatomical Therapeutic Chemical (ATC) code:
  (J05AF13) tenofovir alafenamide

  tenofovir alafenamide
• Medical condition to be studied:
  HIV infection

  Hepatitis B

  Prophylaxis against HIV infection

Population studied

• Age groups:
  • Paediatric Population (< 18 years)

    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Study design details

• Outcomes:
  Outcomes: reported renal outcomes, definition of outcomes, method of measurement, time points measured, types of effect measure (e.g., Odds ratio, Risks ratio, etc.) with 95% confidence intervals (if reported) and statistical power (i.e., p-value) (if reported), unit of measurement, number of participants who discontinued study due to renal AEs (if reported)